News

Was Jim Cramer Right About Bristol-Myers Squibb Co. (BMY)?
We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...
Bristol-Myers Squibb (NYSE:BMY) Collaborates With BioNTech For Antibody Development In Cancer Treatment
Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...
FSU mourns loss of esteemed chemist who synthesized life-saving cancer drug taxol
The Florida State University community mourns the loss of esteemed chemist and noted inventor Robert Holton, whose ...
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's ...
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...
NJBIZ4d
Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal
Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies
Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...
Medical Dialogues1d
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
Bristol Myers Squibb has signed a partnership worth up to $11bn to develop a BioNTech cancer drug that has the potential to beat the world’s bestselling medicine Keytruda.